TITLE

Susceptibilities of healthcare- and community-associated methicillin-resistant staphylococci to the novel des-F(6)-quinolone DX-619

AUTHOR(S)
Shinya Watanabe; Teruyo Ito; Keiichi Hiramatsu
PUB. DATE
December 2007
SOURCE
Journal of Antimicrobial Chemotherapy (JAC);Dec2007, Vol. 60 Issue 6, p1384
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objectives The aim of the study was to test in vitro activities of the novel des-F(6)-quinolone DX-619 against methicillin-resistant staphylococci (MRS) isolated in hospitals and communities and to compare its activity with other quinolones, sitafloxacin and levofloxacin, and antibiotics used for the treatment of methicillin-resistant Staphylococcus aureus infection, including vancomycin, teicoplanin, arbekacin, linezolid and quinupristin/dalfopristin. Methods MICs were determined by the agar dilution method using healthcare-associated MRS (S. aureus including strains with reduced susceptibility to vancomycin, 103; coagulase-negative staphylococci, 87) and community-associated MRS (S. aureus including non-multiresistant oxacillin-resistant strains, 37; coagulase-negative staphylococci, 92). The quinolone resistance-determining regions of gyrA, gyrB, grlA and grlB genes from six strains with reduced susceptibility to DX-619 were sequenced. Results DX-619 showed the lowest MIC90 values for all categories of strains tested, irrespective of the degree of glycopeptide resistance. The six strains with MIC values of >128 mg/L of levofloxacin commonly carried two mutations in gyrA and two mutations in grlA. DX-619 showed potent activity against strains with MIC values of 2 mg/L. Conclusions DX-619 was potent against all MRS tested, suggesting that it would be a promising candidate for the treatment of methicillin-resistant S. aureus infection if sufficient in vivo concentrations were safely attained.
ACCESSION #
27684001

 

Related Articles

  • In vivo antibacterial activity of nemonoxacin, a novel non-fluorinated quinolone. Cong-Ran Li; Yi Li; Guo-Qing Li; Xin-Yi Yang; Wei-Xin Zhang; Ren-Hui Lou; Jing-Fang Liu; Min Yuan; Shan Cen; Li-Yan Yu; Li-Xun Zhao; Jian-Dong Jiang; Xue-Fu You; Philip Huang // Journal of Antimicrobial Chemotherapy (JAC);Nov2010, Vol. 65 Issue 11, p2411 

    Objectives To evaluate the in vivo antibacterial efficacy of nemonoxacin, a novel C8-methoxy non-fluorinated quinolone in murine systemic and local infection models. Methods The efficacy of nemonoxacin in systemic infections was evaluated in mouse peritonitis models using isolates of...

  • Hospital and Community Fluoroquinolone Use and Resistance in Staphylococcus aureus and Escherichia coli in 17 US Hospitals. MacDougall, Conan; Powell, J. Patrick; Johnson, Christopher K.; Edmond, Michael B.; Polk, Ronald E. // Clinical Infectious Diseases;8/15/2005, Vol. 41 Issue 4, p435 

    Background. Fluoroquinolones are widely prescribed in hospitals and the community. Previous studies have shown associations between fluoroquinolone use and isolation of fluoroquinolone-resistant Eshcerichia coli and methicillin-resistant Staphylococcus aureus (MRSA). We performed an...

  • A comparison of moxifloxacin and levofloxacin topical prophylaxis in a fluoroquinolone-resistant Staphylococcus aureus rabbit model. Hiroshi Sasaki; Masamichi Fukuda // Japanese Journal of Ophthalmology;May2008, Vol. 52 Issue 3, p211 

    Abstract Purpose  Moxifloxacin, a fourth-generation fluoroquinolone (FQ), was compared to levofloxacin, a thirdgeneration FQ, for preventing FQ-resistant, methicillin-resistant Staphylococcus aureus (FQrMRSA) endophthalmitis in a rabbit model. Methods  Three regimens of topical...

  • Hardy bacteria looms large in 21st century. Kohl, Martin // Dermatology Times;Oct99, Vol. 20 Issue 10, p1 

    Reports on the emergence of a methicillin-resistant staphylococcus bacteria. Overuse of antibiotics as reason behind the emergence of antibiotic resistant bacteria; Evidence showing that use of antibiotics in treating dermatologic problems may lead to antibiotic resistant bacteria.

  • ANTIMICROBIAL AGENT RESISTANCE. Peterson, Lance R. // Managed Healthcare Executive;Jun2002 Supplement 1, Vol. 12 Issue 6, p20 

    Analyzes the potential impact of emerging resistance to fluoroquinolones, a quinolones antibacterial agent. Properties of fluoroquinolones; Efficacy for treatment of infections; Strategies to prevent the continued development of resistance to fluoroquinolones.

  • A New Approach for the Discovery of Antibiotics by Targeting Non-Multiplying Bacteria: A Novel Topical Antibiotic for Staphylococcal Infections. Yanmin Hu; Shamaei-Tousi, Alireza; Yingjun Liu; Coates, Anthony // PLoS ONE;2010, Vol. 5 Issue 7, p1 

    In a clinical infection, multiplying and non-multiplying bacteria co-exist. Antibiotics kill multiplying bacteria, but they are very inefficient at killing non-multipliers which leads to slow or partial death of the total target population of microbes in an infected tissue. This prolongs the...

  • Breast Abscess and Community-Acquired Resistant Staphylococcus aureus: Case Report and Literature Review. Ventolini, Gary; Barhan, Sheela; Haas, Jennifer // Journal of Gynecologic Surgery;Oct2013, Vol. 29 Issue 5, p251 

    Background: Mastitis is a complication that develops in 1%-24% of breastfeeding women. Breast abscesses complicate mastitis in 5%-11% of cases in the first 12 weeks after birth with Staphylococcus aureus being the most common microorganism retrieved from from breast abscesses. A small number of...

  • Infection control in the community - do we have a problem? Wrobel, Bernadine; Maryon, Beth // Journal of Community Nursing;Jun2006, Vol. 20 Issue 6, p16 

    Provides information on a study which investigated the incidence of methicillin resistant staphylococcus aureus (MRSA) infection in a suburb of London, England. Factors considered in the assessment process; Main routes of infection; Factors contributing to MRSA incidence.

  • Characterization of oxacillin-susceptible mecA -positive Staphylococcus aureus : a new type of MRSA. Yasuko Hososaka; Hideaki Hanaki; Harumi Endo; Yumiko Suzuki; Zenzo Nagasawa; Yoshihito Otsuka; Taiji Nakae // Journal of Infection & Chemotherapy (Springer Science & Business;Apr2007, Vol. 13 Issue 2, p79 

    Abstract  Methicillin-resistant Staphylococcus aureus (MRSA) has been defined as S. aureus having the mecA gene or showing a minimum inhibitory concentration (MIC) of oxacillin higher than 4 mg/l. However, some clinical isolates are mecA-positive and oxacillin-susceptible....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics